Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Michael Brada(University of Liverpool), Siow Ming Lee(University College London Hospitals NHS Foundation Trust), Rhian Gabe(Cancer Research UK), Lindsay C Thompson(MRC Clinical Trials Unit at UCL), Frank Saran(Institut Gustave Roussy), V. Peter Collins(University of Cambridge), Sara Erridge(The University of Texas MD Anderson Cancer Center), R. Rampling(Cancer Research UK), David E. Levy(Cancer Research UK), Kirsten Hopkins(Cancer Research UK), Rao Gattamaneni(The Christie NHS Foundation Trust), Sarah Beall(Cancer Research UK), Sally Stenning(Medical Research Council)
Cited by 248
Related Papers
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
|Nature Genetics|2009|788
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573